A phase I trial (NCT00729664) of BMS-936559, an an-ti-PD-L1 agent, showed that the overall responses (ORs) were observed in patients with melanoma (MEL, 9/52), renal cell carci-noma (RCC, 2/17), NSCLC (5/49), and ovarian cancer (1/17). This evidence concerns the gene CD274 and ovarian cancer.